A Comparison of Clinical and Epidemiological Characteristics of Fatal Human Infections with H5N1 and Human Influenza Viruses in Thailand, 2004–2006 by Shinde, Vivek et al.
A Comparison of Clinical and Epidemiological
Characteristics of Fatal Human Infections with H5N1 and
Human Influenza Viruses in Thailand, 2004–2006
Vivek Shinde
1,2*, Wanna Hanshaoworakul
3, James M. Simmerman
1, Ubolrat Narueponjirakul
3, Wiwan
Sanasuttipun
4, Suchada Kaewchana
4, Darin Areechokechai
3, Kumnuan Ungchusak
3, Alicia M. Fry
1
1Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 2Epidemic Intelligence Service, Centers for Disease Control
and Prevention, Atlanta, Georgia, United States of America, 3Bureau of Epidemiology, Thailand Ministry of Public Health, Nonthaburi, Thailand, 4International Emerging
Infections Program, Thailand Ministry of Public Health – United States Centers for Disease Control and Prevention Collaboration, Ministry of Public Health, Nonthaburi,
Thailand
Abstract
Background: The National Avian Influenza Surveillance (NAIS) system detected human H5N1 cases in Thailand from 2004–
2006. Using NAIS data, we identified risk factors for death among H5N1 cases and described differences between H5N1 and
human (seasonal) influenza cases.
Methods and Findings: NAIS identified 11,641 suspect H5N1 cases (e.g. persons with fever and respiratory symptoms or
pneumonia, and exposure to sick or dead poultry). All suspect H5N1 cases were tested with polymerase chain reaction (PCR)
assays for influenza A(H5N1) and human influenza viruses. NAIS detected 25 H5N1 and 2074 human influenza cases; 17
(68%) and 22 (1%) were fatal, respectively. We collected detailed information from medical records on all H5N1 cases, all
fatal human influenza cases, and a sampled subset of 230 hospitalized non-fatal human influenza cases drawn from
provinces with $1 H5N1 case or human influenza fatality. Fatal versus non-fatal H5N1 cases were more likely to present
with low white blood cell (p=0.05), lymphocyte (p,0.02), and platelet counts (p,0.01); have elevated liver enzymes
(p=0.05); and progress to circulatory (p,0.001) and respiratory failure (p,0.001). There were no differences in age, medical
conditions, or antiviral treatment between fatal and non-fatal H5N1 cases. Compared to a sample of human influenza cases,
all H5N1 cases had direct exposure to sick or dead birds (60% vs. 100%, p,0.05). Fatal H5N1 and fatal human influenza cases
were similar clinically except that fatal H5N1 cases more commonly: had fever (p,0.001), vomiting (p,0.01), low white
blood cell counts (p,0.01), received oseltamivir (71% vs. 23%, p,.001), but less often had $1 chronic medical conditions
(p,0.001).
Conclusions: In the absence of diagnostic testing during an influenza A(H5N1) epizootic, a few epidemiologic, clinical, and
laboratory findings might provide clues to help target H5N1 control efforts. Severe human influenza and H5N1 cases were
clinically similar, and both would benefit from early antiviral treatment.
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Introduction
With the emergence of an epizootic of highly pathogenic avian
influenza A(H5N1) virus among poultry in Southeast Asia in
December 2003, Thailand’s first patients with influenza A(H5N1)
virus infection (hereafter referred to as H5N1 cases) were identified
in January 2004 [1]. As part of Thailand’s public health response,
the National Avian Influenza Surveillance (NAIS) system was
established to detect, investigate, and control H5N1 cases [1,2]. In
the setting of heightened concern over the potential emergence of
a widespread influenza A(H5N1) epidemic among humans, many
thousands of suspect H5N1 cases were investigated and 25 H5N1
cases were eventually confirmed; in addition, 18% of suspect
H5N1 cases tested positive for a human (seasonal) influenza virus
infection (hereafter referred to as human influenza cases) [3]. To
identify possible risk factors or predictors of death due to influenza
A(H5N1) infection and to describe clinical differences between
H5N1 and human influenza cases during the Thailand H5N1
epizootic, we compared clinical characteristics of fatal H5N1 cases
to non-fatal H5N1 cases, and characteristics of fatal H5N1 cases to
fatal human influenza cases detected in the NAIS system.
Methods
Thailand’s National Avian Influenza Surveillance System
(NAIS) was a laboratory-based surveillance system to detect
(human) H5N1 cases. NAIS was established by Thailand’s
Ministry of Public Health (MOPH) in December 2003 following
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Laboratory and epidemiological response components of the
surveillance system have been previously described [1,2,3].
Surveillance for H5N1 cases was healthcare facility-based,
involving all public and private hospitals, outpatient departments,
and freestanding clinics in all provinces of the country.
Surveillance case definitions and case management guidelines
from the MOPH were disseminated to provincial and local public
health offices and to health care facilities. Case definitions were
adapted from official WHO guidelines [4]. A person presenting
to medical care was considered to be a suspect H5N1 case if the
person had a clinical presentation of fever and respiratory
symptoms or evidence of pneumonia, and had at least one of the
following high risk H5N1 virus exposures: 1) contact with sick or
dead birds within 7 days prior to symptom onset, 2) residence in
an area experiencing bird die-offs in the 14 days prior to
symptom onset, or 3) contact with another suspect H5N1 case or
person with pneumonia in the 10 days prior to symptom onset.
After definitive virologic testing (described below), suspect H5N1
cases were determined to be: 1) a laboratory confirmed H5N1
case, or 2) a laboratory confirmed human influenza case (A/
H3N2, A/H1N1, or type B), or 3) excluded for influenza
infection.
Suspect H5N1 case detection and management occurred in the
following way: once a suspect H5N1 case was identified by a
clinician, the patient was isolated, diagnostic respiratory speci-
mens were obtained, antiviral therapy with oseltamivir was
initiated, local and provincial public health authorities were
notified, and the patient was referred to a provincial or regional
hospital for advanced medical care if clinically warranted [1].
Report of a suspect H5N1 case to public health authorities
triggered an epidemiological investigation and a public health
response by district, provincial, and or regional Surveillance and
Rapid Response Teams (SRRTs) [1]. Respiratory specimens
collected from suspect H5N1 cases—consisting of nasopharyn-
geal swabs, throats swabs, or sputum from endotracheal
suction—were tested by a network of 13 regional laboratories
and one central laboratory overseen by the Thailand National
Institute of Health (Thailand NIH); diagnostic virologic testing
consisted of conventional or real-time reverse-transcriptase
polymerase chain reaction (RT-PCR) for highly pathogenic
avian influenza A(H5N1) and human influenza viruses (A(H1N1),
A(H3N2), and type B) [2]. Results of virologic testing were
relayed back to the treating clinicians and public health
authorities via direct notification and through an online web-
based reporting system.
Retrospective Cohort Study
We conducted a retrospective cohort study of H5N1 and
human influenza cases captured in Thailand’s NAIS system
between January 2004 and December 2006. A description of the
study design has been reported previously in a companion study
[3]. Only patients with laboratory confirmed H5N1 or human
influenza who were hospitalized for $1 day were eligible for
inclusion in our study. The final study sample (Figure 1) consisted
of the following three groups of patients: 1) all patients with fatal
and non-fatal laboratory confirmed H5N1 infection; 2) all patients
hospitalized with fatal laboratory confirmed human influenza
infection; and 3) a sampled subset of patients hospitalized with
non-fatal laboratory confirmed human influenza infection. Due to
logistical and resource considerations, the latter sampled subset of
hospitalized non-fatal human influenza cases was selected in a two-
step process by: a) first selecting a convenience sample of 63
hospitals drawn from 25 of 76 Thai provinces in which at least one
H5N1 case or human influenza case death had been reported);
b) then we reviewed all hospitalized human influenza cases notified
in the NAIS system that presented to each of the 63 selected
hospitals. The sampling approach was designed to ensure that
non-fatal human influenza cases were drawn from an epidemio-
logically similar population from which H5N1 and fatal human
influenza cases arose.
Medical charts of sampled patients were reviewed by supervised
teams of trained medical and public health professionals from the
MOPH and the Thailand MOPH-U.S.CDC Collaboration
(TUC) and a form was used to abstract detailed demographic,
epidemiological, clinical, treatment, and outcome data from
medical charts. Data were analyzed using STATA (Version 8,
College Station, TX) statistical software. Disaggregated clinical
and epidemiological data for 17 of 25 H5N1 cases have been
previously reported, however, the data presented here represent a
new abstraction and a complete analysis of all 25 H5N1 cases
detected in Thailand during the study period [2,5,6]. The
statistical analysis consisted of the following three parts: 1) a
comparison of demographic characteristics and high-risk expo-
sures between cases testing positive for H5N1 versus a sample of all
human influenza cases; 2) a comparison of clinical characteristics
associated with fatal and non-fatal outcome among H5N1 cases;
and 3) a comparison of clinical characteristics of fatal H5N1 versus
fatal human influenza cases. A previously published study
compares patients with fatal and non-fatal human influenza from
the NAIS system [3]. The denominators used to calculate
proportions of patients with a given characteristic varied by the
completeness of the available medical chart. Statistical compari-
sons of categorical variables were performed using Pearson’s chi-
square test or Fisher’s exact test, whereas continuous variable were
compared using the Kruskal-Wallis test. All p-values were two-
sided, and considered statistically significant at a p- value ,0.05.
We used univariate logistic regression to estimate unadjusted odd
ratios and 95% confidence intervals (CI) of a fatal outcome among
H5N1 cases given a particular covariate, and also to determine the
unadjusted odds ratios and 95% confidence intervals of a fatal
H5N1 outcome versus a fatal human influenza outcome given a
particular covariate.
This research was carried out with approval from and in
compliance with the standards of the ethical review committees of
the MOPH and the United States Centers for Disease Control and
Prevention (US CDC). Informed consent was not required as data
were analyzed anonymously.
Results
The National Avian Influenza Surveillance (NAIS) system
and the study population
During January 2004 through December 2006, 11,641persons
across Thailand were identified as suspected H5N1 cases in the
NAIS system; among these, 2,074 (18%) persons in 73 of 76 Thai
provinces tested positive for human influenza (A/H1N1, A/
H3N2, or type B) and 25 persons in 19 of 76 provinces tested
positive for H5N1 virus infection [3,7]. Of the 2,074 human
influenza cases, 22 (1%) were fatal and, of the 25 H5N1 cases, 17
(68%) were fatal (Figure 1) [3].
Our study included the following: all 25 H5N1 cases, all 22 fatal
human influenza cases (arising from 15 of 76 provinces), and a
sampled subset of 230 (of 2074 total) hospitalized non-fatal human
influenza cases drawn from 25 of 76 Thai provinces in which at
least one fatal H5N1 or human influenza case had occurred
(Figure 1).
Fatal H5N1 and Human influenza
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time interval to presentation of H5N1 and human
influenza cases
Although human influenza cases were detected in virtually every
Thai province, H5N1 cases were geographically localized to the
central and northern regions where most commercial poultry
production was located. H5N1 cases were detected without a
consistent seasonal pattern; whereas human influenza cases were
most frequently detected during one or two annual periods of peak
influenza activity occurring between July and November or
between January and March (Figure 2) [5,8].
Several differences related to H5N1 virus exposure were
observed between H5N1 and human influenza cases (Table 1).
H5N1 cases were significantly more likely to have one or more
direct, potential high risk exposures to H5N1 virus, for example
consuming sick or dead birds; none had as the only exposure the
presence of sick or dead birds in the neighborhood (Table 1).
Age, gender, and occupation were similar between the two
groups.
Figure 1. Algorithm describing the selection of the study sample from Thailand’s National Avian Influenza Surveillance (NAIS)
system.
doi:10.1371/journal.pone.0014809.g001
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influenza virus infection, Thailand, 2004–2006.
doi:10.1371/journal.pone.0014809.g002
Table 1. Demographic and epidemiologic characteristics of patients with influenza A(H5N1) infection and seasonal human
influenza virus infection, National Avian Influenza Surveillance (NAIS), Thailand, 2004–2006.
H5N1 Influenza Human Influenza
(N=25) (N=252)
Sex Male 16 (64) 147 (59)
Age Median, years (range) 18 (1.6–68) 14 (.08–102)
0–9 yrs 10 (40) 89 (25)
10–19 yrs 4 (14) 64 (25)
20–29 yrs 4 (16) 19 (8)
30–39 yrs 1 (4) 18 (7)
40–49 yrs 3 (12) 20 (8)
.=50 yrs 3 (12) 42 (17)
Occupation Poultry worker 2 (8) 8 (3)
Healthcare worker 0 (0) 1 (,1)
Other 22 (92) 224 (96)
Potential H5N1 virus exposures
Direct exposures Consumed sick or dead birds 7 (39) 8 (5) *
Touched sick or dead birds 16 (70) 69 (32) *
Cared for sick or dead birds 9 (45) 44 (23) *
Butchered sick or dead birds 3 (17) 7 (4) *
Sick or dead birds in household 18 (85) 97 (50) *
Contacted another human H5N1 case 3 (16) 7 (4)
$1 direct exposures 25 (100) 151 (60) *
No direct exposure to H5N1 0 (0) 101 (40)
Indirect** exposures Indirect exposure only 0 (0) 38 (15) *
Indirect plus $1 direct exposures 12 (48) 72 (29)
No known direct or indirect exposures 0 (0) 63 (25) *
*P,0.05.
**Indirect exposures: the presence of sick or dead birds in the patient’s neighborhood.
doi:10.1371/journal.pone.0014809.t001
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presented to hospital later than did human influenza cases
(median: 5 vs. 2 days, p,.01); this difference persisted during
the subsequent two years of surveillance (2005–2006) (data not
shown).
Epidemiological and clinical characteristics of fatal and
non-fatal H5N1 cases
Among H5N1 cases, those with fatal and non-fatal illness were
similar with regard to age (median: 14 vs. 25 years old, p=.86),
presence of an underlying medical condition, presenting symp-
toms, and radiographic evidence of pneumonia or ARDS on an
admission chest X-ray (Table 2). Vomiting was more frequently
observed among those with fatal illness, but was not statistically
significant. However, several notable differences in admission
laboratory testing values were observed between the two groups;
fatal compared to non-fatal H5N1 cases had lower median white
blood cell (WBC) counts, lower median lymphocyte and platelet
counts, and higher mean serum AST and ALT levels.
Similar proportions of fatal and non-fatal H5N1 cases received
treatment with the antiviral agent oseltamivir (71% vs. 57%,
p=.65), an antibiotic agent (100% vs. 100%, p=1), and or a
corticosteroid (29% vs. 43%, p=.65). Clinical complications noted
in H5N1 cases were more frequently present among fatal
compared to non-fatal cases, including respiratory failure
requiring intubation, hypotension requiring inotropic agents,
development of acute respiratory distress syndrome (ARDS), and
need for intensive care unit (ICU) management (Table 2). Similar
clinical intervals between symptom onset, hospitalization, and
oseltamivir treatment were observed between fatal and non-fatal
H5N1 cases. Non-fatal H5N1 cases were hospitalized for a median
of 13 days (range, 1–21), while fatal H5N1 cases died of their
illness within a median of 6 days after hospitalization (range,
2–23).
Epidemiological and clinical characteristics of fatal H5N1
and fatal human influenza cases
Fatal human influenza cases compared to fatal H5N1 cases
tended to be older (median age: 39 vs. 14 years, p=.14), although
not statistically significant, and were significantly more likely to
have a chronic medical condition (Table 3). Clinical symptoms at
admission were similar, except for fever, sore throat, and vomiting
which was significantly more common in fatal H5N1 cases.
Similar proportions of cases in both groups experienced shortness
of breath. A few admission laboratory testing values differed
between the groups; fatal H5N1 cases compared to fatal human
influenza cases had lower median white blood cell (WBC) counts,
lower median neutrophil counts, and a lower median lymphocyte
count (although the latter did not achieve statistical significance).
Fatal cases in both groups had similar (low normal) median values
for platelet counts and mild to moderate elevations in serum liver
enzymes levels (AST and ALT). The initial chest X-ray at
admission was more likely to show radiographic evidence of
pneumonia or ARDS among fatal human influenza cases
compared to fatal H5N1 cases; however, these differences did
not persist if radiographs from the entire hospital course were
considered. Overall, fatal H5N1 cases were significantly more
likely to develop ARDS during the course of illness compared to
fatal human influenza cases.
Among the two groups, fatal H5N1 cases were more likely to
receive oseltamivir that fatal human influenza cases (71% vs. 23%,
p,0.01). However, fatal H5N1 cases experienced greater delays in
the number of median days between symptom onset and hospital
admission, and even more significant delays between symptom
onset and oseltamivir treatment (median: 8 vs. 4 days,
p,.02)(Table 3).
Discussion
During the 2004–2006 influenza A(H5N1) epizootic in Thai-
land, we identified few differences in admission clinical or
epidemiologic characteristics between fatal and non-fatal H5N1
cases; however, the presence of laboratory abnormalities in white
blood cell counts and liver enzymes, hypotension, or ARDS may
suggest a poor prognosis. Compared to patients hospitalized for
human influenza infections, all H5N1 cases had a history of direct
exposure to sick or dead birds. H5N1 cases had a high case fatality
ratio in Thailand, unlike patients with human influenza infection
identified from NAIS. However, severely ill patients with human
influenza infection who subsequently died looked clinically similar
to patients with H5N1 infection. The presence of underlying
medical conditions, lack of measured fever, normal WBC counts,
and the absence of ARDS were the best predictors in severely ill
patients with suspect H5N1 that the infection was due to human
influenza viruses versus H5N1 virus.
Among H5N1 cases, previous reports have described several
admission findings associated with fatal outcome that might help
clinicians risk stratify patients. Among H5N1 cases in Thailand
during 2004–2006, we found that most admission signs and
symptoms, chest radiograph findings, and epidemiologic factors
were not useful in estimating risk for fatal disease. However,
multiple laboratory abnormalities on admission were associated
with a fatal outcome among H5N1 cases. Similar to other reports,
we found that fatal H5N1 cases compared to those who survived,
were more likely to have a lower median white blood cell count
(WBC) or leukopenia [9,10], lower median lymphocyte count or
lymphopenia [10], lower median platelet count or thrombocyto-
penia [9,10,11], elevated serum liver enzymes (AST and ALT)
[9,10,11], and elevated serum BUN and creatinine levels [9]. We
do not have the power to determine specific cut-off values for these
laboratory tests that might predict a poor prognosis. Also, fatal
compared to non-fatal H5N1 cases were more likely to have
circulatory and respiratory failure [10,11], need for ICU
management, and progression to ARDS [11]. There were no
significant differential delays between symptom onset and clinical
care or treatment among the two groups in our study that might
influence our results. Although vomiting was more common
among fatal H5N1 cases in our series, a study by Liem et al
reported diarrhea, not vomiting, to be associated with fatal H5N1
outcome. [10]. We observed no significant differences in the
proportions of cases presenting with diarrhea. The presence of
laboratory abnormalities in WBC counts and liver enzymes,
hypotension, and progression to ARDS likely suggest a poor
prognosis for patients with influenza A (H5N1) virus infection.
We were able to directly compare patients infected with
influenza A (H5N1) virus or human influenza viruses identified
from the same surveillance system. Several epidemiologic factors
may offer clues that the infection is a human influenza infection
versus H5N1 virus infection. Human influenza viruses were most
common during annual peaks in human influenza circulation,
while H5N1 cases had no seasonality. Also, H5N1 cases had a
history of direct exposure from dead or sick birds and were from
provinces with commercial poultry operations; many patients with
human influenza infection had only indirect exposure to dead or
sick birds. Finally, underlying medical conditions that are
associated with complications (including death) from human
influenza infection were present in less than 15% of fatal H5N1
Fatal H5N1 and Human influenza
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with fatal and non-fatal influenza A(H5N1) virus infections.
All H5N1
(N=25)
Non-fatal H5N1
(N=8)
Fatal H5N1
(N=17) p-value
Unadjusted
OR [95% CI]*
Chronic medical conditions
$1 condition 4 (16) 2 (25) 2 (12) 0.57 0.4 [0.04–3.52]
Signs and symptoms at presentation
Fever.38.2uC 23 (96) 6 (86) 17 (100) 0.29 **
Cough 20 (83) 6 (86) 14 (82) 1 1.29 [0.11–15.0]
Sore throat 9 (38) 2 (29) 7 (41) 0.67 0.57 [0.01–3.83]
Dsypnia
{ 17 (81) 4 (57) 13 (76) 0.37 0.41 [0.06–2.66]
Headache 2 (8) 0 (0) 2 (12) 1 **
Myalgia 6 (25) 1 (14) 5 (29) 0.63 0.4 [0.4–4.23]
Altered mental status
1 2 (8) 0 (0) 2 (12) 1 **
Abdominal pain 4 (17) 1 (14) 3 (18) 1 **
Vomiting 12 (50) 1 (14) 11 (65) 0.07 0.09 [0.01–0.94]
Diarrhea 5 (21) 1 (14) 4 (23) 1 0.45 [0.05–5.94]
Laboratory values
White blood cell (WBC) count 5.1 (1.1–18.3) 7.6 (3.1–13.6) 4.1 (1.1–18.3) 0.05 n/a
Neutrophil count 3.9 (1.2–15.6) 4.5 (1.6–8.9) 3.4 (1.2–15.6) 0.11 n/a
Lymphocyte count 1.2 (.1–4.3) 1.8 (.8–4.3) .9 (.1–2.7) 0.02 n/a
Platelet count 172 (77–528) 254 (178–528) 152 (77–304) ,.01 n/a
Hemoglobin 12.3 (9–16.7) 10.4 (9–14) 12.7 (11–16.7) 0.02 n/a
AST 148 (17–1032) 27 (17–306) 181 (34–1032) 0.05 n/a
ALT 50 (7–1048) 20 (7–82) 55 (26–1048) 0.04 n/a
BUN 12 (4–61) 9 (4–9) 22 (7–61) 0.05 n/a
Creatinine 1 (.2–2.8) 0.7 (.2–.8) 1.4 (.5–2.8) 0.03 n/a
Admission chest X-ray
Pneumonia
" 4 (50) 7 (41) 11 (44) 1 0.7[0.13–3.79]
Pneumonia
" or ARDS 4 (50) 7 (41) 11 (44) 1 0.7 [0.13–3.79]
Result of any chest X-ray
Pneumonia
" 15 (60) 4 (50) 11 (65) 0.67 1.83 [0.33–10.09]
Pneumonia
" or ARDS 20 (80) 4 (50) 16 (94) 0.02 16.0 [1.38–185.4]
Complications
Hypotension 13 (57) 0 (0) 13 (81) ,.001 **
Respiratory failure 17 (71) 0 (0) 17 (100) ,.001 **
ARDS 14 (56) 0 (0) 14 (82) ,.001 **
Need for ICU 17 (68) 0 (0) 17 (100) ,.001 **
Key Intervals
Symptom onset to first medical care 4 (1–14) 4 (3–14) 3 (1–10) 0.2 n/a
Symptom onset to hospital admission 4 (2–18) 4.5 (3–18) 4 (2–10) 0.34 n/a
Symptom onset to oseltamivir treatment 7 (4–21) 7 (5–7) 8 (4–21) 0.39 n/a
Hospital admission to oseltamivir treatment 2.5 (0–14) 2 (0–3) 3 (0–14) 0.28 n/a
Hospital admission to death or discharge n/a 13 (1–21) 6 (2–23) n/a n/a
N/a: not applicable;
*unadjusted OR and 95% CI of a fatal H5N1 outcome among H5N1 cases;
{dyspnea: defined as any recorded difficulty breathing or shortness of breath in any age group, or in a child less than age 5, the presence of stridor or chest in-drawing;
1altered mental status: defined as any recorded presence of altered mental status, confusion, or unconsciousness;
"pneumonia: defined as the presence of alveolar infiltrates, interstitial infiltrates, or lobar consolidation on chest X-ray;
**not possible to calculate an unadjusted OR.
doi:10.1371/journal.pone.0014809.t002
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Fatal H5N1
Fatal Human
Influenza p-value
Unadjusted
OR [95% CI]*
(N=17) (N=22)
Chronic medical conditions
$1 condition 2 (12) 15 (68) 0.001 0.06 [0.01–0.35]
Sign and Symptoms Presentation
Fever.38.2uC 17 (100) 9 (41) ,.001 **
Cough 14 (82) 15 (68) 0.46 0.46 [0.1–2.13]
Sore throat 7 (41) 1 (5) 0.01 0.07 [0.01–0.63]
Dsypnia
{ 13 (76) 16 (73) 1 0.82 [0.19–3.54]
Headache 2 (12) 0 (0) 0.18 **
Myalgia 5 (29) 1 (5) 0.07 0.11 [0.11–1.01]
Altered mental status
1 2 (12) 6 (27) 0.37 0.36 [0.06–2.04]
Abdominal pain 3 (18) 0 (0) 0.07 **
Vomiting 11 (65) 4 (18) ,.01 0.12 [0.03–0.53]
Diarrhea 4 (23) 2 (9) 0.37 0.33 [0.05–2.04]
Laboratory values
White blood cell (WBC) count 4.1 (1.1–18.3) 8.7 (0.9–34.7) 0.01 n/a
Neutrophil count 3.4 (1.2–15.6) 6.0 (.05–29.5) 0.02 n/a
Lymphocyte count .9 (.1–2.7) 1.5 (.4–5.0) 0.09 n/a
Platelet count 152 (77–304) 156 (90–392) 0.61 n/a
Hemoglobin 12.7 (11–16.7) 12.2 (8.5–17.7) 0.41 n/a
AST 181 (34–1032) 161 (48–2289) 0.88 n/a
ALT 55 (26–1048) 70 (18–444) 0.47 n/a
BUN 22 (7–61) 25 (7–92) 0.46 n/a
Creatinine 1.4 (.5–2.8) 1.3 (.2–10.4) 0.81 n/a
Admission Chest X-ray
Pneumonia
" 7 (41) 18 (82) 0.02 0.15 [0.04–0.66]
Pneumonia
" or ARDS 7 (41) 19 (86) ,.01 0.11 [0.02–0.52]
Any Chest X-ray
Pneumonia
" 11 (65) 18 (82) 0.28 0.4 [0.09–1.77]
Pneumonia
" or ARDS 16 (94) 19 (86) 0.62 2.53 [0.24–26.72]
Complications
Hypotension 13 (81) 20 (91) 0.63 2.3 [0.34–15.75]
Respiratory failure 17 (100) 22 (100) n/a n/a
ARDS 14 (82) 7 (32) ,.001 0.1 [0.02–0.46]
Need for ICU 17 (100) 15 (68) 0.01 n/a
Key intervals
Symptom onset to first medical care 3 (1–10) 2 (0–7) 0.22 n/a
Symptom onset to hospital admission 4 (2–10) 2 (0–7) 0.02 n/a
Symptom onset to oseltamivir treatment 8 (4–21) 4 (4–7) 0.02 n/a
Hospital admission to oseltamivir treatment 3 (0–14) 1 (0–3) 0.1 n/a
Hospital admission to death or discharge 6 (2–23) 3.5 (0–68) 0.09 n/a
N/a: not applicable;
*unadjusted OR and 95% CI of a fatal H5N1 outcome versus a fatal human influenza outcome;
{dyspnea: defined as any recorded difficulty breathing or shortness of breath in any age group, or in a child less than age 5, the presence of stridor or chest in-drawing;
1altered mental status: defined as any recorded presence of altered mental status, confusion, or unconsciousness;
"pneumonia: defined as the presence of alveolar infiltrates, interstitial infiltrates, or lobar consolidation on chest X-ray;
**not possible to calculate an unadjusted OR.
doi:10.1371/journal.pone.0014809.t003
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had chronic medical conditions. These differences may offer some
clues when laboratory testing is delayed or lacking to target control
efforts to identify and prevent secondary human transmission
H5N1 cases during a large epizootic outbreak.
Clinically, patients with severe human influenza infections that
resulted in death were generally similar to patients with influenza
A (H5N1) infection; shortness of breath was commonly observed
on presentation and platelet counts and liver enzymes levels on
initial laboratory assessment were similar. Also, similar proportions
of cases in both groups had disease progression complicated by
circulatory and respiratory failure. Although these clinical
characteristics have been previously described in large series of
severe and fatal H5N1 cases [7,9,10,11,12,13], we found that they
were not unique to H5N1 cases. The lack of underlying medical
conditions, presence of a measured fever and low WBC counts,
and the presence of ARDS were the best predictors that the
infection was H5N1 virus versus human influenza virus among
severely ill patients identified by NAIS.
Although the NAIS system was developed to find H5N1 cases, it
eventually detected 80 times more human influenza cases [3],
primarily as a consequence of three factors: 1) the ubiquitous
nature of poultry exposures amongst the surveillance population,
2) overlapping clinical respiratory syndromes, and consequently
non-specific case definitions, and 3) a comprehensive and specific
laboratory-based molecular diagnostic testing of all suspect H5N1
cases. In our study cohort, all confirmed H5N1 cases had at least
one documented direct H5N1 exposure; in contrast, among those
testing positive for human influenza, 40% had no documented
direct H5N1 exposure (overall, 15% had only indirect exposures,
and 25% had no direct or indirect exposure). All laboratory
confirmed H5N1 cases met the broad clinical case definition of a
suspected H5N1 case disseminated by the MOPH. However, had
a more narrow WHO suspect H5N1 case definition been adopted,
four fatal and four non-fatal H5N1 cases might have been missed
due to the initial absence of documented shortness of breath as
required under the WHO suspect H5N1 case definition. Although
using a broader surveillance case definition was resource intensive,
the MOPH case definition was nonetheless a reasonable approach
for case ascertainment given the risks of misdiagnosing and
delaying treatment for a highly fatal H5N1 infection. Lastly, as
noted in previous studies, we observed delays in care between
onset of H5N1 symptoms and medical attention or initiation of
antiviral therapy, especially among H5N1 cases and fatal human
influenza cases [5,7,9,11,12,13,14,15,16,17,18,19]. The benefit of
oseltamivir is greatest early in the disease course for both severe
infections due to either H5N1 or human influenza [7].
Decentralization (to the extent possible) of access to oseltamivir
and the promotion of clinical awareness of severe influenza virus
infections and the benefits of early antiviral treatment among
frontline clinicians might improve clinical outcomes for many
patients with suspect H5N1 infection during an influenza A
(H5N1) epizootic.
Our study was subject to several limitations. NAIS was a passive
surveillance system, and H5N1 cases may have been missed as a
consequence of under-reporting and or under-detection. In
addition, the characteristics of the patients with human influenza
infection from NAIS are different from those identified from
surveillance for human influenza infections. Consequently, adults
$65 years of age and very young children with human influenza,
with no poultry exposure, were not represented. Clinical and
epidemiologic data on individual cases varied according to the
completeness of medical records. Also, information on potential
H5N1 exposures were extracted retrospectively and may have
been more complete for confirmed H5N1 cases. Due to our small
sample size, we may not be able to detect some differences in
clinical characteristics between fatal and non-fatal H5N1 cases and
human influenza cases. Finally, inferences regarding the clinical
presentation of H5N1 cases are limited to the clade one H5N1
viruses circulating in Thailand and the surrounding region during
the study period and may not be representative of other clades of
H5N1 virus known to cause human disease in other parts of the
world.
As a result of Thailand’s strong public health response to the
emergence of influenza A(H5N1) virus infection in humans, we
were provided a rare opportunity to compare H5N1 cases and
human influenza cases identified by the same surveillance system.
In lieu of laboratory diagnostics, history of direct exposure to dead
or sick birds and lack of underlying medical conditions that are
associated with complications due to human influenza may
provide clues for targeting H5N1 control efforts. Fatalities from
human influenza infection were uncommon. However, patients
with severe human influenza infection had a clinical presentation
that overlapped considerably with H5N1 cases. All of these
patients, those with H5N1 infection and those with severe human
influenza infection, would benefit from early empiric antiviral
treatment.
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